Background: While our previous work has shown that replacing existing vaccines with thermostable vaccines can relieve bottlenecks in vaccine supply chains and thus increase vaccine availability, the question remains whether this benefit would outweigh the additional cost of thermostable formulations. Methods: Using HERMES simulation models of the vaccine supply chains for the Republic of Benin, the state of Bihar (India), and Niger, we simulated replacing different existing vaccines with thermostable formulations and determined the resulting clinical and economic impact. Costs measured included the costs of vaccines, logistics, and disease outcomes averted. Results: Replacing a particular vaccine with a thermostable version yielded cost savings in many cases even when charging a price premium (two or three times the current vaccine price). For example, replacing the current pentavalent vaccine with a thermostable version without increasing the vaccine price saved from $366 to $10,945 per 100 members of the vaccine's target population.
Introduction
While our previous work has shown that replacing existing vaccines with thermostable vaccines can relieve bottlenecks in vaccine supply chains and thus increase vaccine availability [1] , the question remains whether this benefit would outweigh the additional cost of thermostable formulations. All World Health Organization (WHO) prequalified vaccines currently require storage in refrigerators or freezers as exposure to higher temperatures may result in the denaturation of the proteins in the vaccine rendering them impotent. However, many vaccine supply chains in low-and middle-income countries have shortages in refrigerated (or even lower temperature) storage and transport capacity to accommodate all of the vaccine doses that must eventually make it to the population [2, 3] . Making certain vaccines thermostable would allow these vaccines to be stored outside refrigerators or freezers, thus freeing up space for vaccines that still require cooler or cold temperatures. More vaccine doses reaching the population can protect more mothers and children from infectious diseases, thus saving medical costs and productivity losses. However, [1, 3, 6, 7] (4 levels: 1 national store, 7 regional stores, 42 districts, 644 integrated health centers). Table 1 lists the current and newly introduced vaccines and their characteristics for each location. All models used 2013 population estimates and reported costs are in 2016 US dollars ($US).
Comparing standard versus thermostable formulations of each vaccine
In the baseline scenario for each of the three supply chains, all vaccines represent presentations currently available plus introduced vaccines, with each vaccine requiring either refrigeration or freezing depending on the temperature susceptibility profile of that specific vaccine. Making a vaccine thermostable meant that the vaccine could remain outside cold storage without suffering degradation. Thermostable formulations would have the same overall shelf life and the same physical presentation (e.g., doses per vial, packaged volume) otherwise. Different experiments varied the price of thermostable vaccines from the current vaccine price (i.e., no price premium for a thermostable version of the vaccine) up to 300% of the current vaccine price.
Each experiment consisted of running the supply chain simulation for the course of one year. As the simulation proceeded, logistics costs accrued for labor, storage, transport, and buildings. The formula for total logistics costs for each supply chain is below: In addition, the formula for total procurement costs is given below: The following formulas then determined the medical costs saved, disability-adjusted life years (DALYs) averted, and productivity losses averted from the infections prevented:
Direct medical costs saved ¼ VPI Averted Â Average medical cost per infection DALYs averted ¼ VPI Averted Â Average DALYs per infection Productivity losses averted ¼ DALYs Averted Â GNI per capita
We ranged these results from low to high with a base case scenario. Each input for incidence, medical costs per case and DALYs per case was pulled from the literature ( Table 2 ). When ranges were not available from the literature, we varied the average incidence and medical cost per case by 50% and the average DALYs per case by 20% and used these as low and high inputs.
Additionally, we calculated the incremental cost-effectiveness ratio (ICER) of stabilizing a vaccine compared to not stabilizing using the following formula:
þ medical costs incurred in thermostable scenarioÞ À logistics þ procurement þ medical costs incurred in ð baseline scenarioÞÞ DALYs incurred in baseline scenario ð = À DALYs incurred in thermostable scenarioÞ Cost-effectiveness is defined as an ICER ratio <3x GDP per capita, while highly cost-effective is <1x GDP per capita. GDPs per capita were $762 for Benin, $1598 for India, and $359 for Niger in 2015 US dollars ($) [8] .
All reported results for logistics costs, procurement costs, vaccine availability, and doses administered represent the mean. When not reported the standard deviation was 1% or less. 
Results

Current situation with no vaccines thermostable (Baseline)
Our simulation runs of the current vaccine supply chains yielded the following results over the course of one simulated year: in Benin, 5,294,835 doses were administered resulting in 80% overall vaccine availability (the vaccine availabilities fall within the ranges of WHO/UNICEF-estimated per vaccine coverage in Benin 2013, 64-92%, with the vaccine availability at each location consistent with observed geographic variability) [9] ; in Bihar, 14,506,033 doses and 50% availability; and in Niger, 7,302,396 doses and 46% availability (which falls within the WHO/UNICEF-estimated per vaccine coverage in Niger 2013, 38-71%) [10] . Our team did not have Bihar, India, WHO/UNICEF-estimated vaccine coverage data. Validation of all three country models also consisted of comparing model results with actual stock data and wastage rates provided by in-country partners. Table 3 shows the cost impact of making each vaccine thermostable (per 100 persons in the target population) and Table 4 shows the ICER values across each thermostable scenario, vaccine cost, and location.
A thermostable pentavalent vaccine (Penta)
Making the Pentavalent vaccine thermostable improved overall vaccine availability in Benin to 86%, averting 7427 (4192-12,242) infections and 17,012 (6304-33,399) disability-adjusted life years (DALYs). At current vaccine price, procurement costs increased by $812,000 (as indicated in Section 2, where not reported, standard deviation is <1%), while logistics costs decreased by $9000, medical costs by $11,033,000 ($3,232,000-$25,662,000) and productivity losses by $14,290,000 ($5,295,000-$28,055,000), resulting in $24,521,000 ($7,724,000-$52,914,000) total savings. In Bihar, overall vaccine availability improved to 56%, averting 40,117 (22,011-67,874) infections and 96,518 (35,110-237,604) DALYs. At current price, procurement costs increased by $7,383,000, while logistics costs decreased by $6000, medical costs by $50,694,000 ($14,832,000-$132,262,000) and productivity losses by $154,429,000 ($56,176,000-$380,166,000), resulting in $197,746,000 ($63,631,000-$505,052,000) total savings. In Niger, overall vaccine availability improved to 69%, averting 62,268 (36,761-100,002) infections and 130,382 (49,117-256,131) DALYs. At current price, procurement costs increased by $6,473,000, while logistics costs decreased by $230,000, medical costs by $83,454,000 ($24,438,000-$193,321,000) and productivity losses by $50,849,000 ($19,156,000-$99,891,000), resulting in $128,059,000 ($37,350,000-$286,969,000) total savings.
As shown in Table 4 , thermostabilized Penta was cost-saving or highly cost-effective at all modeled price points (current, 2x, and 3x). In most cases, the reduction in medical costs generated savings above the increase in associated procurement costs. Only when Penta was priced at 3x the current price, using the low estimate for disease incidence and medical costs, were the costs greater than the savings per DALY averted. Even in this scenario, however, Penta thermostability was highly cost-effective. Black represents highly cost-effective (< GDP/capita) and gray represents cost-effective (<3x GDP/capita). Annual GDPs per capita are $762 for Benin, $1,598 for India, and $359 for Niger in 2015 US dollars ($). [6] Black represents highly cost-effective (<GDP/capita) and gray represents cost-effective (<3x GDP/capita). Annual GDPs per capita are $762 for Benin, $1598 for India, and $359 for Niger in 2015 US dollars ($) [6] .
A thermostable pneumococcal conjugate vaccine (PCV)
Making PCV thermostable improved overall vaccine availability in Benin to 86%, averting 2194 (1398-3476) infections and 4643 (1950-9688) DALYs. At current vaccine price, procurement costs increased by $1,621,000, while logistics costs decreased by $9000, medical costs by $1,885,000 ($546,000-$4,415,000) and productivity losses by $3,990,000 ($1,638,000-$8,138,000), resulting in $4,174,000 ($572,000-$10,941,000) total savings. In Bihar, overall vaccine availability improved to 56%, averting 5488 (3482-9626) infections and 17,171 (8025-42,343) DALYs. At current price, procurement costs increased by $3,542,000, while logistics costs decreased by $6000, medical costs by $2,346,000 ($673,000-$6,726,000) and productivity losses by $27,474,000 ($ 12,840,000-$67,749,000), resulting in $26,284,000 ($9,977,000-$ 70,940,000) total savings. In Niger, overall vaccine availability improved to 58%, averting 19,762 (12,654-30,952) infections and 39,553 (16,488-81,584) DALYs. At current price, procurement costs increased by $9,104,000, while logistics costs decreased by $163,000, medical costs by $17,577,000 ($5,108,000-$40,929,000) and productivity losses by $15,426,000 ($6,430,000-$31,818,000), resulting in $24,062,000 ($2,598,000-$63,806,000) total savings.
Thermostable PCV was cost-saving or highly cost-effective in each location at its current price (Table 4 ). At 2x current price, PCV remained highly cost-effective or cost-effective when the average and high inputs for incidence, medical costs and DALYs were used. However, given the high price of the vaccine, doubling the price, using low inputs for incidence, medical costs and DALYs, led to PCV no longer being cost-effective in Benin and Niger.
A thermostable bacille calmette-guérin vaccine (BCG)
Making BCG thermostable improved overall vaccine availability in Niger to 55%, averting 2876 (1829-4399) infections and 5050 (1914-10,092) DALYs. At current price, procurement costs increased by $666,000, while logistics costs decreased by $16,000, medical costs by $2,809,000 ($817,000-$6,521,000) and productivity losses by $1,970,000 ($746,000-$3,936,000), resulting in $4,129,000 ($914,000-$9,807,000) total savings. At each price point (current, 2x, and 3x) in Niger, thermostable BCG was costsaving or highly cost-effective (Table 4 ).
A thermostable yellow fever vaccine (YF)
Making YF thermostable improved overall vaccine availability in Niger to 55%, averting 3061 (1963-4657) infections and 5215 (2045-10,264) DALYs. At current price, procurement costs increased by $1,909,000, while logistics costs decreased by $16,000, medical costs by $2,979,000 ($867,000-$6,908,000) and productivity losses by $2,034,000 ($798,000-$4,003,000), resulting in $3,120,000 (-$228,000-$9,019,000) total savings. At current price, under all input conditions, thermostable YF was costsaving or cost-effective in Niger (Table 4) . However, when the price was 2x or 3x the current price, using low inputs for incidence, medical costs, and DALYs per case, a thermostable YF vaccine was not cost-effective. When the average and high inputs were used, thermostable YF was cost-effective at 2x and 3x the current price.
Discussion
Our results show that making vaccines thermostable can bring cost savings under a number of different circumstances including when a price premium is charged for the thermostable formulations. Logistics costs decreased because the introduction of thermostable vaccines relieved bottlenecks and in turn reduced the number of additional trips needed. However, with bottlenecks being reduced, vaccine costs increased since the system could then handle the ordering of more vaccine (although the increased costs from more vaccines were partially offset by reductions in wastage. The most substantial decrease occurred in medical costs and productivity losses decreased as more vaccines reached the target population and could then avert more cases of disease. Therefore, the net result was a decrease in overall costs. These findings help quantify the potential economic impact of thermostable vaccines, providing support for their development. Of course, the impact may vary depending on the severity of constraints in a supply chain and the burden of disease in the population. However, as previous studies have shown, many lower-and middle-income counties suffer from significant bottlenecks [1] [2] [3] 11, 12] , while the burden of major vaccine-preventable disease remains high [13] .
Thermostable vaccines are currently at a crossroads, which helped motivate this study. A decade ago, interest in thermostable vaccines grew until some suggested that thermostable vaccines would have limited value as long as other vaccines still required the cold chain [12] . In other words, the main value of thermostable vaccines seemed to be in their ability to obviate the need for any refrigerators and freezers. However, our previous study showed that there are additional benefits even when the cold chain remains: thermostable vaccines could help alleviate the constraints and bottlenecks of the supply chain by freeing up cold space that could then be used for other vaccines and items [1] . This current study then quantifies that value in economic, epidemiologic, and clinical terms.
Computational modeling can help guide the development of new technologies such as thermostable vaccines by showing their potential impact and value and how these may change based on changing characteristics and conditions. It can also help prioritize which types of vaccines should be the focus of such research and development. Currently, there are efforts to develop thermostable formulations of antigens such as influenza, polio, and rotavirus [14] [15] [16] . However, it is unclear which formulations of these may ultimately reach the market and when, since developing thermostable vaccines requires surmounting a number of technological challenges. For example, any new stabilizer, adjuvant, or excipient must not sacrifice the potency or safety of the vaccine. Regardless, our study suggests that the effort required to surmount such challenges may ultimately be worthwhile.
Limitations
No model can capture every aspect of a supply chain and factor that may affect the impact of a thermostable vaccine. Our experiments assumed that a thermostable formulation of a vaccine would otherwise have the same characteristics such as doses per vial, packaged volume, and efficacy. Our estimates of vaccine efficacy, infection rates, and the costs and DALYs associated with different vaccine-preventable diseases came from different studies identified from extensive searches of the literature. Each of these studies has associated limitations. When data were not available for a specific location, we used data from similar locations, transforming the data where appropriate (e.g., using purchase power parity to translate medical costs). Our study also did not consider other challenges in the supply chain and vaccines that may occur in the future.
Conclusions
Our study quantified the potential economic impact of thermostable vaccines. Replacing a particular vaccine with a thermostable version yielded cost savings in many cases even when charging a price premium of two or three times the current vaccine price. Savings in medical costs and productivity and in some cases logistics costs could outweigh even significant price premiums charged for thermostable formulations of vaccines. While developing thermostable vaccines will require overcoming technological challenges, our study suggests that the effort entailed may ultimately be worthwhile.
